Transfusion-Associated Bacterial Sepsis

Korsak, Jolanta

doi:10.5772/28129

Cited by 1 publication

(2 citation statements)

References 63 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Since the transmissibility of violet-blue light in platelet concentrates is in the same region as (if not slightly lower than) plasma (0.1-0.3% compared to 0.08-3.6%, respectively), based on data from this study and Maclean et al (8), it would be expected that similar pathogen inactivation would be observed in human plasma. Nevertheless, future work is required to fully assess the inactivation of a range of pathogens associated with transfusion transmitted infections including bacterial spores, viruses and protozoa (1)(2)(3)(4).…”

Section: Discussionmentioning

confidence: 99%

“…Since the implementation of blood transfusion, risk reduction measures including donor screening, sample diversion and nucleic acid testing (NAT) for HIV, HBV and HCV have significantly improved the safety of blood components (1). Nevertheless, the low but known risk of bacterial contamination remains the second most common cause of fatal transfusion-associated reactions, after ABO incompatible transfusion-associated fatal reactions due to clerical errors (2). In response to this, three main areas of avoidance, detection and elimination have been explored with the common goal of providing a near zero-risk blood supply (3).…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Violet‐blue 405‐nm Light‐based Photoinactivation for Pathogen Reduction of Human Plasma Provides Broad Antibacterial Efficacy Without Visible Degradation of Plasma Proteins

Stewart

Tomb

Ralston

et al. 2022

Photochem & Photobiology

View full text Add to dashboard Cite

In transfusion medicine, bacterial contamination can occur in ex vivo stored blood plasma, and there are continued efforts to improve blood safety and reduce the risk of transfusiontransmitted infections. Visible 405-nm violet-blue light has demonstrated potential for in situ pathogen reduction in ex vivo stored plasma and platelet concentrates. This study investigates the broad-spectrum antibacterial efficacy and compatibility potential of 405-nm light for treatment of blood plasma. Human plasma seeded with bacteria at a range of densities (10 1 -10 3 , 10 4 -10 6 , 10 7 -10 8 CFU mL −1 ) was exposed to 360 J cm −2 405-nm light (1 h at 0.1 W cm −2 ), with this fixed dose selected based on the initial analysis of inactivation kinetics. One-dimensional protein mobility analysis and measurement of advanced oxidation protein products (AOPP) was conducted to evaluate compatibility of the antimicrobial dose with plasma proteins and, identify upper levels at which protein degradation can be detected. Broad-spectrum antibacterial efficacy was observed with a fixed treatment of 360 J cm −2 , with 98.9-100% inactivation achieved across all seeding densities for all organisms, except E. coli, which achieved 95.1-100% inactivation. At this dose (360 J cm −2 ), no signs of protein degradation occurred. Overall, 405-nm light shows promise for broad-spectrum bacterial inactivation in blood plasma, while preserving plasma protein integrity.

show abstract